Prognostic value of pre-treatment 18F-FDG-PET uptake in small-cell lung cancer

Basit Öğe Kaydı
dc.contributor.authorAktan, Meryem
dc.contributor.authorKoc, Mehmet
dc.contributor.authorKanyilmaz, Gul
dc.contributor.authorYavuz, Berrin Benli
dc.date.accessioned2024-02-23T13:59:55Z
dc.date.available2024-02-23T13:59:55Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractPurpose Small-cell lung cancer (SCLC) is an aggressive disease, despite an initially favorable response to treatment, and its prognosis is still poor. Multiple parameters have been studied as possible prognostic factors, but none of them are reliable enough to change the treatment approach. F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) is a novel imaging technique for staging of SCLC. The aim of this study was to evaluate the prognostic value of pre-treatment FDG-PET parameters on clinical outcome in limited stage (LS) SCLC patients treated with curative thoracic radiotherapy (RT) and chemotherapy. Clinical records of 46 LS-SCLC patients with pre-treatment FDG-PET imaging were retrospectively reviewed. Patients were treated with definitive RT for a total dose of 50-60 Gy and chemotherapy. The clinical endpoints were progression-free survival (PFS) and overall survival (OS). The median age was 59 (range 30-82) years, and median follow-up time was 23.2 months (range 5-82.8 months). Median OS was 30.9 months for pre-treatment tumor maximum standardized uptake value (SUVmax) < 9.3 and 20.6 months for SUVmax ae9.3 (p = 0.027) and PFS was 55.6 months for SUVmax < 9.3 and 38.6 months for SUVmax ae9.3 (p = 0.16). Median OS was 73 months for pre-treatment lymph node SUVmax < 5.8 and 21 months for ae5.8 (p = 0.01) and PFS was 38.6 months (range 6.8-70.3 months) for SUVmax-LN ae5.8; all patients with SUVmax-LN < 5.8 were alive (p = 0.07). Median survival time was 28.2 months (range 21.7-34.7 months) for patients younger than 65 and 8.7 months (range 5.7-11.8 months) for those ae65 years (p = 0.00). Pre-treatment FDG-PET uptake may be a valuable tool to evaluate prognosis in SCLC patients. Patients with a higher pre-treatment FDG uptake may be considered at increased risk of failure and may benefit from more aggressive treatment approaches.en_US
dc.identifier.doi10.1007/s12149-017-1178-z
dc.identifier.endpage468en_US
dc.identifier.issn0914-7187
dc.identifier.issn1864-6433
dc.identifier.issue6en_US
dc.identifier.pmid28516335en_US
dc.identifier.scopus2-s2.0-85019559671en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage462en_US
dc.identifier.urihttps://doi.org/10.1007/s12149-017-1178-z
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11350
dc.identifier.volume31en_US
dc.identifier.wosWOS:000404218300004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofAnnals Of Nuclear Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFdg-Peten_US
dc.subjectLung Canceren_US
dc.subjectSmall-Cell Lung Canceren_US
dc.subjectPrognosisen_US
dc.titlePrognostic value of pre-treatment 18F-FDG-PET uptake in small-cell lung canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu